CAPR

Capricor Therapeutics Stock Price

4.10
0.08 (1.99%)
Upgrade to Real-Time
Afterhours (Closed)
4.10

Low
1.40

52 Week Range

High
12.32

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Capricor Therapeutics Inc CAPR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.08 1.99% 4.10 20:00:00
Open Price Low Price High Price Close Price Prev Close
4.08 3.97 4.1638 4.01 4.02
Bid Price Ask Price Spread News
3.98 4.08 0.10 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,571 318,130 $ 4.06 $ 1,290,235 1,194,555 1.40 - 12.32
Last Trade Time Type Quantity Stock Price Currency
19:55:11 12 $ 4.03 USD

Capricor Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 83.83M 20.45M 19.96M $ 1.01M $ - -2.07 -5.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Capricor Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CAPR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.444.5273.974.17163,631-0.34-7.66%
1 Month5.125.473.974.76231,172-1.02-19.92%
3 Months5.288.403.976.42660,138-1.18-22.35%
6 Months4.95888.403.325.35697,336-0.8588-17.32%
1 Year1.5012.321.407.072,376,1412.60173.33%
3 Years1.6512.320.25265.911,066,0032.45148.48%
5 Years3.3412.320.25264.90870,7610.7622.75%

Capricor Therapeutics Description

Capricor Therapeutics Inc is a United State-based clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, and other medical conditions. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions.


Your Recent History
NASDAQ
CAPR
Capricor T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.